

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

JAN 2022


Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).


Fund Information

Inception Date	: 18 Oct 21
Fund Size	: USD 1,555,818.13
Fund Currency	: USD
Type of fund	: Equity
Valuation	: Daily
Custodian Bank	: Bank DBS Indonesia
Annual Management Fee	: 2.50%
Net Asset Value/Unit ⁽³⁾	: USD 0.9827
Bloomberg Code	: MATKGMU IJ

Performance Since Inception




Monthly Performance Last 3 Years



Risk Classification

Risk classification is based on type of fund.



Allocation

Equity	: 80 - 100 %
Money Market	: 0 - 20 %

Portfolio

Equity Onshore	: 0.00%
Equity Offshore	: 143.09%
Money Market	: -43.09%

Top 5 Holdings

1 BlackRock World Healthscience Fund D2 USD

Fund Performance

Performance in USD per (31/01/22)							
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ⁽¹⁾	5 yr ⁽¹⁾
MANTKG	-6.76%	-3.76%	n/a	-6.76%	n/a	n/a	-1.73%
BM ⁽²⁾	-7.65%	-4.12%	N/A	-7.65%	n/a	n/a	-0.12%
Yearly Performance							
	2021	2020	2019	2018	2017	2016	2015
MANTKG	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BM ⁽²⁾	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Note

- Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- The benchmark is MSCI World Health Care Index.
- The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Investment Manager Commentary

Global health science equity was volatile in January, mainly affected by sentiment regarding US monetary policy. Uncertainty on The Fed's policy weighs on the market following The Fed's hawkish statement in early January that opens the possibility of rate hike in Q1-2022. The Fed also signals the possibility of unwinding its balance sheet (quantitative tightening). This policy uncertainty result in higher market volatility for global equity. We remain very alert to shifts in the COVID 19 dynamic with the emergence of Omicron, and continue to monitor developments on this front. We raised exposures to companies with investments in vaccine producer and diagnostics supplier. Biotechnology sector also particularly attractive with cheap valuation and innovative product pipeline. Longer term, the secular growth drivers supporting healthcare demand continue, with aging population that will create secular demand and growth for healthcare products and services.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 25 sales offices, Manulife Indonesia serves more than 2 million customers in Indonesia. PT Asuransi Jiwa Manulife Indonesia is registered and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit www.manulife.co.id



www.manulife.co.id



Manulife Indonesia



@Manulife_ID



Manulife_ID



Manulife Indonesia